Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the disease market
- Related reports
MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Countries and regions included in this report
- Seven major market assessment
- Current and future market overview
- Regional market dynamics
- Class market dynamics
- Comparison with previous market forecast
- Total ADHD market downgraded since 2008 forecast
- Launch of neuronal nicotinic receptor agonists represents the most
fundamental change to pipeline ADHD drug forecast
- Rest of the world snapshot
- Rest of the world sales accounted for just 2.4% of the ADHD market in
2008
BRAND DYNAMICS
- Major market events
- US study links ADHD stimulant treatments and pediatric sudden death
- New NICE guidelines published in September 2008
- Overview of competitive landscape
- Update of key marketed ADHD drugs
- Adderall XR (amphetamine extended release, Shire)
- Vyvanse (lisdexamfetamine dimesylate, Shire)
- Concerta (methylphenidate, Johnson & Johnson)
- Daytrana (methylphenidate transdermal system, Shire)
- Strattera (atomoxetine, Eli Lilly)
- Metadate franchise (methylphenidate hydrochloride, Shire)
- Liquadd (dextroamphetamine sulfate, Auriga Laboratories Inc)
- Forecasted pipeline products
- Intuniv (guanfacine hydrochloride, Shire)
- Clonicel (clonidine hydrochloride, Addrenex/Sciele)
- ABT-894 (, Abbott/NeuroSearch)
- ABT-089 (pozanicline, Abbott)
- Update of unforecasted pipeline products
- Histamine H3 Antagonist (Johnson & Johnson)
- AZD3480 (Ispronicline, AstraZeneca/Targacept)
- Eltoprazine (PsychoGenics Inc)
- SPN-810 (Supernus Pharmaceuticals)
- MK-0249 (Merck)
- Discontinued projects
- SPD-465 (mixed amphetamine salt, Shire)
BIBLIOGRAPHY
- Journal papers/Books
- Websites
- Datamonitor reports
APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Derivation of sales forecasts and pricing trends
- Forecast methodology
APPENDIX B
- Contributing experts
- Conferences attended
- Report methodology
TABLES
- Table: Performance of the attention-deficit hyperactivity disorder (ADHD)
markets in the US, 5EU and Japan, 2004 - 08
- Table: Sales forecasts of drugs currently marketed for attention-deficit
hyperactivity disorder (ADHD) in the seven major markets ($m), 2008 - 2018
- Table: Comparison of leading branded drug sales ($m) for attention-deficit
hyperactivity disorder (ADHD) in the seven major markets and the rest of the
world (ROW), 2008
- Table: Limitations of Gould et al.' s (2009) study into sudden death in
children and use of stimulant medication
- Table: Top 6 branded drug sales ($m) for attention-deficit hyperactivity
disorder (ADHD) in the seven major markets, 2008 - 2018
- Table: Key products in late-stage R&D pipeline for attention-deficit
hyperactivity disorder (ADHD), 2009
- Table: Off-label prescribing of Vyvanse, 2008
- Table: Summary of Phase III results for Intuniv in attention-deficit
hyperactivity disorder (ADHD), announced May 2008 - May 2009
- Table: Summary of Phase III results for Clonicel (clonidine hydrochloride)
for attention-deficit hyperactivity disorder (ADHD), announced in 2008 - 09
- Table: Clinical trial summary for ABT-894 (sofinicline) in
attention-deficit hyperactivity disorder (ADHD)
- Table: Clinical trial summary for ABT-089 (pozanicline) in
attention-deficit hyperactivity disorder (ADHD)
- Table: Top-line results from Phase II study of AZD3480 in adult
attention-deficit hyperactivity disorder (ADHD)
- Table: Key facts: Phase IIa trial of SPN-810 in children with
attention-deficit hyperactivity disorder (ADHD) and persistent serious conduct
problems
- Table: Datamonitor' s estimated launch dates for in attention-deficit
hyperactivity disorder (ADHD) products in the seven major markets, 2009 - 2018
- Table: Patent expiry dates for the approved in attention-deficit
hyperactivity disorder (ADHD) products in the seven major markets, 2009 - 2018
FIGURES
- Figure: Sales of attention-deficit hyperactivity disorder (ADHD) drugs,
($m) in the US, 5EU and Japan, 2004 - 08
- Figure: Key events impacting the attention-deficit hyperactivity disorder
(ADHD) market, April 2008 - April 2009
- Figure: Attention-deficit hyperactivity disorder (ADHD) market value in
the seven major markets, 2005 - 2018
- Figure: Impact of key events on the attention-deficit hyperactivity
disorder (ADHD) market, 2009 - 2018
- Figure: Attention-deficit hyperactivity disorder (ADHD) market value ($m)
in the seven major markets, 2008 - 2018
- Figure: Revenues of stimulant and non-stimulant attention-deficit
hyperactivity disorder (ADHD) drugs across the seven major markets, 2005 - 2018
- Figure: Comparison of Datamonitor' s updated seven major market
attention-deficit hyperactivity disorder (ADHD) market forecast to 2018 with
previous 2008 market forecast to 2017
- Figure: Datamonitor' s previous and updated sales ($m) forecast for total
pipeline attention-deficit hyperactivity disorder (ADHD) drugs in the seven
major markets, 2008 - 2018
- Figure: The global attention deficit hyperactivity disorder (ADHD) market
split by region, 2008
- Figure: Rest of the world sales in the attention-deficit hyperactivity
disorder (ADHD), major depressive disorder and insomnia markets in 2007 and
2008
- Figure: Revenue market share of the leading branded attention-deficit
hyperactivity disorder (ADHD) drugs, 2004 - 08
- Figure: Shire' s attention-deficit hyperactivity disorder (ADHD) franchise
forecast ($m), across the seven major markets 2008 - 2018
- Figure: Shire' s promotional spend for Adderall XR and Vyvanse in the US,
2006 - 08
- Figure: Datamonitor' s 2008 and updated sales ($m) forecast for Shire' s
Adderall XR in the seven major markets, 2008 - 2018
- Figure: Approval of key brands for the treatment of adult
attention-deficit hyperactivity disorder (ADHD)
- Figure: Datamonitor' s updated sales ($m) forecast for Shire' s Vyvanse
(lisdexamfetamine) in the seven major markets, 2008 - 2018
- Figure: Concerta sales revenue ($m) across the seven major markets,
markets, 2008 - 2018
- Figure: Datamonitor' s updated sales ($m) forecast for Daytrana in the
seven major markets, 2008 - 2018
- Figure: Datamonitor' s 2008 and updated sales ($m) forecast for Strattera
in attention-deficit hyperactivity disorder (ADHD) in the seven major markets,
2008 - 2018
- Figure: Datamonitor' s updated sales ($m) forecast for the Metadate
franchise in the seven major markets, 2008 - 2018
- Figure: Datamonitor' s 2008 and updated sales ($m) forecast for Liquadd in
the seven major markets, 2008 - 2018
- Figure: Attention-deficit hyperactivity disorder (ADHD) sales ($m) for
Intuniv in the seven major markets, 2008 - 2018
- Figure: Attention-deficit hyperactivity disorder (ADHD) sales ($m) for
Clonicel in the seven major markets, 2009 - 2018
- Figure: Attention-deficit hyperactivity disorder (ADHD) sales ($m) for
ABT-894/ABT-089 in the seven major markets, 2009 - 2018
|
Related Report
|
View Cart
